drugset / Trial / NCT02454478

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

NCT02454478

Phase 1 Completed 7 enrolled Eisai Inc.
NaSingle-groupOpen-labelTreatment

Summary

Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.

Timeline

Start
2015-07-01
Primary completion
2017-05-29
Completion
2017-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule
Background Everolimus Small molecule

Indications